Picture the argenx commercial team on the morning of May 7, 2026. $1.3 billion in first-quarter global product net sales — up 63% year-over-year from $790 million in Q1 2025. Seventeen consecutive quarters of VYVGART growth. In three days, the FDA’s PDUFA clock on seronegative generalized myasthenia gravis runs out. The spreadsheets look perfect. The question nobody in that room is saying out loud: is the best of this story already priced in?

That tension — between a commercial engine running at full throttle and a pipeline whose next chapter is simultaneously promising and uncertain — is the actual story behind argenx’s Q1 print. The street will celebrate the 63% growth. The smarter read is what the growth reveals about where VYVGART’s next incremental patient comes from, how hard that patient will be to find, and what happens if empasiprubart stumbles before it can share the burden.

argenx built its dominance on efgartigimod’s mechanism: a first-in-class IgG Fc antibody fragment targeting the neonatal Fc receptor, which drives pathogenic IgG clearance. In a disease like generalized MG — where auto-antibodies destroy neuromuscular junction signaling — that mechanism is genuinely differentiated. The company now holds approximately 65.4% of the FcRn inhibitors market projected at $2.36 billion globally in 2025. But market share at that altitude means you also absorb the most competitive pressure as fast followers sharpen their own programs. The label expansion strategy argenx is executing right now is effectively a moat-deepening exercise — and the next 90 days will tell you whether the moat holds.

The Label Expansion Gambit

The seronegative gMG PDUFA on May 10 is the most immediately consequential regulatory event in argenx’s calendar. Standard AChR-antibody-positive MG patients represent the bulk of the diagnosed population, but seronegative patients — including MuSK-positive, LRP4-positive, and triple seronegative subgroups — have historically been left with limited options because they don’t carry the antibody profile that most approved therapies were designed around. The FDA accepted this sBLA with priority review in January 2026, a signal that the agency sees the unmet need as genuine.

Approval here does two things that pure revenue projections miss. First, it removes one of the few remaining clinical objections a neurologist can raise when considering VYVGART — “we don’t have a seronegative label” disappears from the conversation. Second, and more commercially significant, it sets the stage for the ocular MG expansion. ADAPT OCULUS hit its primary endpoint and was presented at the 2026 American Academy of Neurology Annual Meeting, and argenx has signaled a planned sBLA submission. If VYVGART ultimately carries a label that covers seropositive gMG, seronegative gMG, and oMG simultaneously, it becomes structurally difficult for any competitor to argue a patient-type carve-out in MG.

That sequencing matters more than any single data readout. argenx’s CEO Karen Massey — appointed formally on May 6, one day before this earnings release — described VYVGART as having “the potential to become the first and only approved therapy across MG” pending these decisions. That language in a CEO’s first public statement post-appointment is not accidental; it is a commercial positioning statement delivered through a regulatory narrative.

But the MG story, however clean, has a ceiling. The global CIDP market is projected to reach $2.46 billion in 2026, growing at an 8.1% CAGR — and VYVGART already holds an approved indication there. The incremental CIDP patient is becoming the marginal patient, which is why the myositis readout from the ALKIVIA study in Q3 2026 carries disproportionate strategic weight. Rheumatology is argenx’s next adjacency, and its success there would meaningfully extend the revenue trajectory without cannibalizing the neurology franchise.

The Second Bet Nobody Is Modeling Correctly

Zoom out to empasiprubart and the commercial picture gets genuinely interesting — and genuinely underappreciated. Most analyst models treat empasiprubart as a future optionality item, a line item with a wide confidence interval. The mechanism justifies more attention. Empasiprubart is a complement factor C2 inhibitor, selectively blocking the classical and lectin pathways. In multifocal motor neuropathy, the Phase 2 ARDA study enrolled 54 participants randomized 2:1 against placebo, with supportive efficacy signals that justified advancing to the EMPASSION registrational study, with topline results expected Q4 2026.

MMN is a rare, progressive peripheral nerve disease where patients are typically dependent on intravenous immunoglobulin for symptom management — a high-burden, high-cost standard of care with no approved biologic alternative. The commercial analogy is instructive: look at what happened to the CIDP treatment paradigm when VYVGART entered with a mechanism-first positioning against a background of chronic IVIg dependency. Neurologists were not immediately enthusiastic — until they were. The payer conversation followed the prescriber conviction, not the other way around.

If empasiprubart delivers a clean Phase 3 readout in MMN, argenx does not simply add a revenue line. It proves the company can originate and commercialize a second distinct biological mechanism — and that proof matters enormously for how BD partners and potential acquirers value the entire argenx platform through 2030.

argenx reported $4.2 billion in global product net sales for full year 2025, treating approximately 19,000 patients. The Vision 2030 ambition targets 50,000 patients across 10 labeled indications. The math on that ambition runs through empasiprubart — VYVGART alone, even fully label-expanded, does not get you there.

What the 63% Growth Number Conceals

Here is the counterintuitive read on argenx’s Q1 print: the growth rate is impressive, but it is also a function of a relatively low prior-year base in indications that were still building commercial infrastructure. That dynamic compresses over time. By Q1 2027, argenx will be comparing against $1.3 billion quarters — and 63% growth against that base requires either a step-change in patient volumes or new revenue sources from label expansions that have not yet launched.

The VYVGART SC autoinjector, expected in 2027 for all approved indications, is one lever. Patient convenience drives adherence and can shift market share at the margin, particularly in conditions like CIDP where patients are managing long-term subcutaneous regimens alongside other chronic disease management. But convenience improvements are execution plays, not transformative ones. The real volume question is whether seronegative and oMG approvals unlock meaningfully underpenetrated patient pools or whether those patients are already partially captured through off-label prescribing and compassionate use.

Any BD team running a rare disease immunology asset should be watching argenx’s ALKIVIA myositis readout in Q3 2026 with acute commercial interest. A positive result in myositis would signal that the FcRn mechanism translates cleanly into rheumatological indications — which would raise the floor price for every partnering negotiation in that space. Conversely, a miss would put significant pressure on argenx’s rheumatology narrative just as ARGX-109, its anti-IL-6 candidate, is still years from commercial relevance. The risk is sequenced asymmetrically: a myositis win accelerates everything; a miss lands in a year when empasiprubart is also at its most binary.

Karen Massey steps into the CEO chair at a moment when the commercial infrastructure is already world-class and the growth narrative is intact. The harder task is preventing a single-asset identity from hardening around VYVGART before empasiprubart and the next-generation FcRn molecules — ARGX-213, described as Phase 3-ready, and ARGX-124, currently in Phase 1 — can generate their own clinical and commercial gravity. At $1.3 billion per quarter and growing, argenx has the capital to get there. The seventeen consecutive VYVGART growth quarters are the foundation. The Q4 2026 empasiprubart readout in MMN is the first real test of what argenx becomes next.

References

  1. argenx SE / GlobeNewswire — “argenx Reports First Quarter 2026 Financial Results and Provides Business Update,” May 7, 2026
  2. argenx SE / BioSpace — “argenx Reports First Quarter 2025 Financial Results and Provides Business Update,” May 8, 2025
  3. Future Market Insights — “FcRn Inhibitors Market: Global Forecast 2025”